Eyewire News: The Podcast
Eyewire News: The Podcast

12.03.25

Eylea HD Approved for RVO and Extended Dosing

Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease.  Learn more about your ad choices. Visit megaphone.fm/adchoices

View full description +

MORE EPISODES

Show More